SMTI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SMTI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Sanara MedTech's Free Cash Flow for the three months ended in Mar. 2024 was $-1.66 Mil. Sanara MedTech's Revenue for the three months ended in Mar. 2024 was $18.54 Mil. Therefore, Sanara MedTech's FCF Margin % for the quarter that ended in Mar. 2024 was -8.96%.
As of today, Sanara MedTech's current FCF Yield % is -1.31%.
The historical rank and industry rank for Sanara MedTech's FCF Margin % or its related term are showing as below:
During the past 13 years, the highest FCF Margin % of Sanara MedTech was 7.37%. The lowest was -64.38%. And the median was -18.40%.
The historical data trend for Sanara MedTech's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanara MedTech Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
FCF Margin % | Get a 7-Day Free Trial | -32.91 | -36.43 | -23.05 | -13.75 | -5.40 |
Sanara MedTech Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
FCF Margin % | Get a 7-Day Free Trial | -11.40 | -11.00 | 5.58 | -5.10 | -8.96 |
For the Medical Instruments & Supplies subindustry, Sanara MedTech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Sanara MedTech's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Sanara MedTech's FCF Margin % falls into.
FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.
Sanara MedTech's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as
FCF Margin | = | Free Cash Flow (A: Dec. 2023 ) | / | Revenue (A: Dec. 2023 ) |
= | -3.511 | / | 64.99 | |
= | -5.40 % |
Sanara MedTech's FCF Margin for the quarter that ended in Mar. 2024 is calculated as
FCF Margin | = | Free Cash Flow (Q: Mar. 2024 ) | / | Revenue (Q: Mar. 2024 ) |
= | -1.66 | / | 18.537 | |
= | -8.96 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Sanara MedTech's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Eric D Major | director | 751 MILLER DRIVE SE, LEESBURG VA 20175 |
Zachary B. Fleming | officer: President - Surgical Div. | 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102 |
Shawn M. Bowman | officer: President - Wound Care Div. | 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102 |
Rebecca E Mcmahon | officer: President - R&D | 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102 |
Sara N Ortwein | director | 5959 LAS COLINAS BOULEVARD, IRVING TX 75039-2298 |
Robert Andrew Desutter | director | 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102 |
Eric D Tanzberger | director | 1929 ALLEN PARKWAY, HOUSTON TX 77219 |
Christopher A. Morrison | officer: President - Telehealth Svcs. | 1200 SUMMIT AVENUE, SUITE 414, FORT WORTH TX 76102 |
Roszell Iii Mack | director | 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102 |
Cgi Cellerate Rx, Llc | 10 percent owner | C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735 |
Catalyst Rochal, Llc | 10 percent owner | C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735 |
Bradley J. Gurasich | 10 percent owner | C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735 |
J Michael Carmena | director, officer: Principal Executive Officer | 1200 SUMMIT AVE STE 414, FORT WORTH TX 76102 |
Michael D. Mcneil | officer: Chief Financial Officer | 1200 SUMMIT AVE, STE 414, FORT WORTH TX 76102 |
Catalyst Group, Inc. | 10 percent owner | 1375 ENCLAVE PARKWAY, HOUSTON TX 77077 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 07-05-2022
By GuruFocusNews GuruFocusNews • 06-15-2022
By GuruFocusNews GuruFocusNews • 04-04-2022
By Value_Insider Value_Insider • 11-01-2022
By PurpleRose PurpleRose • 07-15-2022
By Marketwired • 08-01-2023
By GuruFocusNews GuruFocusNews • 05-16-2022
By PurpleRose PurpleRose • 08-15-2022
By PurpleRose PurpleRose • 08-03-2022
By GuruFocusNews GuruFocusNews • 07-05-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.